Dovato demonstrated non-inferior efficacy compared to TAF-based regimens
Oral S1P receptor modulator hit both primary endpoints in a phase III trial
Therapy failed to improve invasive disease-free survival in high-risk patients
Two trials will involve over 6,000 participants at sites in and outside the US
Bristol Myers Squibb’s Zeposia boosts remission rates over placebo in ulcerative colitis patients kblankenship Fri, 10/09/2020 – 13:50
Virologists have shown that a treatment with the anti-malaria drug hydroxychloroquine does not limit SARS-CoV-2 coronavirus replication in […]
Researchers used a second-generation pro-drug called MP-Pt(IV) to target the deadly cells of glioblastoma tumors and found mice […]
Hypertension is a harbinger of a huge cardiovascular disease burden globally, with an estimated one in three adults […]
Has Donald Trump launched a new space mission?For once this has nothing to do with the US president, […]
The NHS will face a full blown second surge of covid-19 without urgent action to reverse the sustained […]